relapsing-remitting multiple sclerosis

She was diagnosed with relapsing-remitting multiple sclerosis at seventeen years of age.

It has reduced the rate of relapses in relapsing-remitting multiple sclerosis by over half.

It is also used to treat relapsing-remitting multiple sclerosis.

Bartlet suffers from relapsing-remitting multiple sclerosis, which at one time put the future of his presidency in doubt.

President Bartlet was diagnosed with relapsing-remitting multiple sclerosis (MS) in 1992.

From the moment Lauren had become pregnant fifteen months before, she'd enjoyed a sabbatical from her long struggle living with relapsing-remitting multiple sclerosis.

Many people with relapsing-remitting multiple sclerosis can go days, weeks, months, or years without major changes in their symptoms, but then suddenly, an MS relapse hits.

But in clinical trials, it reduced the frequency of flareups by about 30 percent for people in the early stages of relapsing-remitting multiple sclerosis.

The symptoms vary widely, and in about a third of the cases come and go unpredictably, a form of the disease known as relapsing-remitting multiple sclerosis.

The phase II trial involved patients with early, relapsing-remitting multiple sclerosis who had not been treated with other MS drugs.

Most of these drugs are approved only for Relapsing-Remitting multiple sclerosis (RRMS).

Relapsing-remitting multiple sclerosis is a form of MS in which symptoms randomly flare up (relapse) and then improve or fade (remission).

Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: A phase I/II study.

Intravenous Immunoglobulin in Relapsing-Remitting Multiple Sclerosis - A Dose-Finding Trial.

This was followed a year later by Betaseron, a beta interferon, the first treatment for relapsing-remitting multiple sclerosis and made by Berlex Laboratories Inc.

This treatment is effective for slowing disease progression and activity in relapsing-remitting multiple sclerosis and reducing attacks in secondary progressive multiple sclerosis.

In patients with relapsing-remitting multiple sclerosis, dimethyl fumarate (BG-12, Biogen) significantly reduced relapse and disability progression in a phase 3 trial.

The earliest clinical presentation of relapsing-remitting multiple sclerosis is the clinically isolated syndrome (CIS), that is, a single attack of a single symptom.

A phase III trial into treatment of relapsing-remitting Multiple Sclerosis showed a reduction in relapse rate, but no statistically significant reduction in accumulated disability, when used as a first-line therapy.

In two Phase III clinical trials, fingolimod reduced the rate of relapses in relapsing-remitting multiple sclerosis by over half compared both to placebo and to the active comparator interferon beta-1a.

Medications are modestly effective at decreasing the number of attacks in relapsing-remitting multiple sclerosis and in reducing the accumulation of brain lesions, which is measured using gadolinium-enhanced magnetic resonance imaging (MRI).

A phase II trial of Dirucotide as a potential therapy for relapsing-remitting multiple sclerosis (RRMS), MINDSET-01, failed to achieve its primary endpoint of reduced relapse rate.

April 15, 2010 (Toronto) - Nearly 71% of people with early relapsing-remitting multiple sclerosis (MS) treated with the experimental MS drug alemtuzumab showed no evidence of disease activity four years into a study, researchers report.

Study co-author Alasdair Coles, PhD, tells WebMD that phase III trials will soon be under way to determine if the benefits of alemtuzumab outweigh the risks in patients with early relapsing-remitting multiple sclerosis.